FDA Brief

Warning letters Drugs

FDA warning letter to

Guangzhou Orchard Aromatherapy & Skin Care Co., Ltd.

High riskIssued Jul 20, 2022Posted Jul 26, 2022Center for Drug Evaluation and Research | CDER

Guangzhou Orchard Aromatherapy & Skin Care refused FDA records requests for its over-the-counter hand sanitizers, leading to import alert.

What happened

FDA reviewed import records showing multiple shipments of over-the-counter drug products that declared Guangzhou Orchard Aromatherapy & Skin Care Co., Ltd. as the drug manufacturer. FDA sent records requests on August 9 and August 27, 2021, spoke with the firm's registered U.S. agent on October 26, 2021, and sent a follow-up request on November 24, 2021, but the firm did not respond or provide the records. FDA placed all drugs manufactured by the firm on Import Alert 66-79 on May 16, 2022, and publicly warned consumers not to use its hand sanitizer drug products.

What FDA found

  1. The firm did not respond to FDA's repeated requests for records about its drug manufacturing and product quality.

    section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)
  2. Refusing to permit access to or copying of records required by section 704(a) is a prohibited act.

    section 301(e) of the FD&C Act, 21 U.S.C. 331(e)

What FDA wants

Respond in writing within 15 working days. The company may provide information for FDA to consider or ask FDA to schedule an inspection.

Who should pay attention

  • brands that buy finished hand sanitizer from this contract manufacturer
  • retailers and distributors selling artnaturals or Orchard de Flore hand sanitizers
  • OTC drug firms using foreign manufacturers that do not answer FDA records requests

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Zenzi Pharmaceutical Industries Pvt. Ltd.

    Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.

    High risk
  3. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  4. Gulf States International, Inc.

    Gulf States International refused FDA requests for OTC drug manufacturing records, FDA says.

    Medium